Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CM Life Sciences III
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
CM Life Sciences III was created to identify and acquire an innovative life sciences company. In late 2021, it merged with EQRx, providing up to $1.8 billion for EQRx’s pipeline of advanced clinical drug candidates in oncology and inflammatory diseases, including Phase 3 assets aumolertinib and sugemalimab
- Industry
- Investors
02
Partnerships
SB Northstar LP (SoftBank)FidelityFranklin TempletonInvusRock Springs CapitalBain Capital Life SciencesBVF PartnersBoxer CapitalAvidity PartnersAndreessen HorowitzMubadala Investment CompanyVerily (within PIPE and trust account)
Beyond the preview
Go deeper on CM Life Sciences III.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CM Life Sciences III.